Targets Archives - Page 4 of 7 - Biotech on the Web

Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis

Sep 13, 2020Biotech (General), Clinical Trials, Multiple Sclerosis

New post hoc data from Phase III ASCLEPIOS trials showed newly diagnosed, treatment-naïve patients experienced reductions in annualized relapse rates, MRI lesion activity and reductions in time to disability worsening when treated with Kesimpta vs teriflunomide(1) Additional safety data in over 1,800 patients who continued Kesimpta treatment or switched therapy from previous studies reinforce the […]

Trump Administration’s Operation Warp Speed Accelerates AstraZeneca COVID-19 Vaccine to be Available Beginning in October

Aug 24, 2020Biotech (General), Clinical Trials, COVID-19

Responding to President Trump’s call to develop 300 million doses of SARS-CoV-2 vaccine by January under Operation Warp Speed, the U.S. Department of Health and Human Services (HHS) and AstraZeneca are collaborating to make available at least 300 million doses of a coronavirus vaccine called AZD1222, with the first doses delivered as early as October […]

NOVARTIS IMMUNO-ONCOLOGY DRUG CANDIDATE FAILS SKIN CANCER TRIAL

Aug 24, 2020Cancer, Clinical Trials

ZURICH (Reuters) – Swiss drugmaker Novartis said on Saturday that its investigational spartalizumab immuno-oncology drug mixed with the approved medicines Tafinlar and Mekinist failed in a late-stage trial for a type of advanced skin cancer. The drug did not improve progression-free survival in previously untreated patients with BRAF V600 mutation-positive cutaneous melanoma, compared to Tafinlar […]

A look at Inovio’s Philly local coronavirus vaccine-in-progress

Aug 12, 2020Biotech (General), COVID-19

Operation Warp Speed, the federal government’s multi-agency push to develop a COVID-19 vaccine, is promising to provide 300 million doses by January 2021. That means funding for several of the top candidates. Moderna, one of the leaders of the pack, is already in Phase III trials after creating its first vaccine in a record-breaking 42 […]

Israeli scientist uses microbubbles to explode cancer cells

Aug 10, 2020Biotech (General), Cancer

An international team of researchers led by an Israeli scientist has developed a noninvasive technology to kill breast cancer cells, an innovation that in the future could perhaps also be used to treat diseases such as brain cancer, Alzheimer’s and Parkinson’s. The groundbreaking technique, developed by Tel Aviv University’s Tali Ilovitsh during her post-doctorate period […]

Celularity announces the activation of first California Clinical Trial Site following CIRM Grant Award to Advance Treatments for COVID-19

Aug 6, 2020Biotech (General), Clinical Trials, Corporate News, COVID-19

FLORHAM PARK, N.J., Aug. 5, 2020 /PRNewswire/ — Celularity today announced that it has been awarded a $750,000 COVID-19 Project grant by the California Institute for Regenerative Medicine (CIRM), one of the three clinical awards targeting the coronavirus. This grant will support California Institutions participating in the Phase I/II clinical trial of human placental hematopoietic stem cell derived natural killer (NK) […]

Pfizer could earn $15B-plus in COVID-19 vaccine sales: analyst

Jul 28, 2020Biotech (General), COVID-19

On the heels of Pfizer’s $1.95 billion COVID-19 vaccine deal with the U.S. government, one analyst says the drugmaker could earn many more billions in revenue on its potential vaccine—if the program succeeds. At $1.95 billion for 100 million doses, Pfizer’s deal sets a price-per-dose of $19.50, which Bloomberg Intelligence analyst Sam Fazeli sees as […]

Partnered and backed by AbbVie, but cancer I-O biotech Tizona targeted by Gilead

Jul 22, 2020Biotech (General), Biotech Stocks To Watch, Cancer

Headed up by Scott Clarke, an ex-Roche exec who served as its global head of oncology partnering for Asia and emerging markets, the cancer immunotherapy company is working on several early assets, including TTX-030, a CD39-targeting antibody that last year attracted AbbVie’s interest and, according to preclinical data, seems to block an immune-inhibiting pathway in […]

Novartis promises zero profit for 15 symptomatic COVID-19 drugs in low-income countries

Jul 17, 2020Biotech (General), COVID-19

Novartis’ generic hydroxychloroquine may have little use in COVID-19, but the Swiss pharma still wants to contribute its low-cost drugs in some way in the current fight. Novartis’ Sandoz unit will offer 15 generic and over-the-counter medicines at zero profit to developing countries during the pandemic, the company said Thursday. The portfolio covers widely used antibiotics and […]

Imvax Inc. Raises $112 Million in Series C Financing

Jul 16, 2020Biotech (General), Cancer, Clinical Trials

Imvax Inc. Raises $112 Million in Series C Financing Funds to support Phase 2 Clinical Development of IGV-001 for treatment of Glioblastoma multiforme, Phase 1 research into additional solid tumor indications and build out of the operational capabilities PHILADELPHIA, JULY 16, 2020 – Imvax, Inc., a clinical-stage biotechnology company whose groundbreaking personalized neo-antigen immunotherapy, IGV-001, is being […]